TMCnet News
InvestSource, Inc.: ACTCellerate Technology Licensed to BioTime, Inc by Advanced Cell Technology(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:12082008 Stocks in the news: Advanced Cell Technology, Inc. (OTC: ACTC), Altus Pharmaceuticals Inc. (NASDAQ: ALTU), OMRIX Biopharmaceuticals, Inc. (NASDAQ: OMRI), Health Discovery Corporation (OTCBB: HDVY) August 11, 2008 -- Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC) announced today that it has granted an exclusive license to Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc., to use "ACTCellerate" embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology. Under the agreement, ACT received an upfront payment of $250,000, and is eligible to receive an 8% royalty on sales of products, services, and processes that utilize the licensed technology. Once a total of $1,000,000 of royalties has been paid, no further royalties will be due. ACT has an option to reacquire rights to use the ACTCellerate technology for the development of certain types of stem cells for human therapeutic use in fields related to its core business. ACTCellerate is a recently discovered technology that allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate between embryonic stem cells and fully differentiated cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of embryonic stem cells. Using the ACTCellerate platform technology over 140 distinguishable novel progenitor cell lines have already been created, scaled-up, and banked. These unique cell lines may possess the ability to become a wide array of products never before available to the medical community, with potential applications in research, drug discovery, and human regenerative stem cell therapy. "We are pleased that we were able to enter into an agreement to monetize non-core technologies," said William M. Caldwell, IV, ACT's Chairman and CEO. "We continue to seek potential licensees and joint venture partners to share in the development costs of many of our promising clinical programs." Additional information about ACTCellerate technology appears in the May 2008 edition of the journal Regenerative Medicine (www.futuremedicine.com/toc/rme/3/3). ACTCellerate is a trademark of Advanced Cell Technology, Inc. August 11, 2008 -- Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announces its Phase 3 efficacy trial of TrizytekTM (porcine-free enzymes) in patients with cystic fibrosis (CF) successfully met its primary endpoint of improvement in fat absorption. The Company released results from its 163 patient, double-blind, placebo-controlled trial of Trizytek, an enzyme replacement therapy for patients with pancreatic insufficiency. Trizytek is a stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. Altus' Trizytek Phase 3 clinical program is the largest ever conducted to evaluate the efficacy and safety of pancreatic enzyme replacement therapy in cystic fibrosis patients. Detailed trial results will be presented at the North American Cystic Fibrosis Conference in October 2008. In cystic fibrosis patients with exocrine pancreatic insufficiency, Trizytek demonstrated a statistically significant improvement of fat absorption over placebo through the measurement of the coefficient of fat absorption (CFA). The primary efficacy analysis was an intent to treat (ITT) analysis in the sub-group of patients with severe malabsorption (baseline CFA below 40). In addition, data were analyzed for the overall group. Patients treated with Trizytek had a statistically significant improvement in CFA compared to placebo. In the Trizytek CFA<40 group, there was an improvement in the mean CFA of 20.2 (80% change from baseline). In the placebo CFA<40 group, there was an increase in mean CFA of 5.1 (24% change from baseline). The mean difference between groups for the change in CFA was 15.1 (p=0.001). August 11, 2008 -- OMRIX Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today the appointment of Asaf Alperovitz, as Chief Financial Officer (CFO) effective October 23, 2008. Mr. Alperovitz has been CFO from 2005 of Tefron LTD, a multinational manufacturing company listed on both the New York (NYSE: TFR) and Tel-Aviv (TASE: TFRN) Stock Exchanges. From 2003 until 2005, Mr. Alperovitz was CFO of Corigin Ltd., an international enterprise software company. Prior to 2003, Mr. Alperovitz held a variety of management positions with Ernst & Young in Israel and the United States. His client-base included publicly traded companies in the U.S., Europe and Israel and his experience includes mergers and acquisitions as well as equity and debt public offerings. In his position as CFO of Omrix, Mr. Alperovitz will be responsible for finance, strategic, operational and financial planning, investor relations and information technology systems. Mr. Alperovitz is a Certified Public Accountant and holds a Bachelor's degree in Accounting and Economics and a Masters in Business Administration from Tel-Aviv University. August 11, 2008 -- Health Discovery Corporation ("HDC") (OTCBB: HDVY) today announced that HDC's new gene-based molecular diagnostic test for prostate cancer which has now successfully completed its Phase III double-blind clinical trial and is now ready for commercialization, will be presented at the upcoming Biomarker Discovery Europe 2008 conference in Dublin, Ireland on October 2-3. The new prostate cancer test will be performed at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed. CEO of Health Discovery Corporation, was invited to participate as a Distinguished Presenter on the Faculty of the Biomarker Discovery Europe 2008 Summit. Dr. Barnhill will present the results from Phase I, Phase II and Phase III double-blind clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center which demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. His presentation will emphasize that to date, 322 prostate tissues have been tested - and that the combined results of the recently completed double-blind clinical validation studies demonstrated on the new gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%. Market Wrap for August 11, 2008 - The stock market posted a solid gain on Monday, with notable strength in financials and retailers. The financial sector ended the day with a gain of 1.7%, a substantial retreat from its session high when it was up as much 3.8%. Consumer discretionary (+2.5%) stocks were an area of strength. Retailing stocks posted a solid advance of 4.8%, after being up as much as 8.0%. Amazon.com (AMZN 88.05, +7.54) soared 9.4% after Citi said that sales of Amazon's electronic book reader, Kindle, appear to be much stronger than expected. The energy sector (-0.4%) was a laggard, with a steep drop in coal stocks (-5.2%) acting as a major drag. The materials sector (-0.4%) also posted a loss. Mining stocks came under pressure after gold (-3.8%) and silver (-4.4%) prices tumbled as the dollar rose 0.5%. In corporate news, Waste Management (WMI 36.09, +0.08) raised its offer to purchase Republic Services (RSG 35.05, +0.19) to $37 per share, or $6.73 billion, from $34 per share. Food products company Sysco (SYY 31.11, +1.24) said its latest quarterly earnings rose 12% year-over-year to $0.55 per share, which topped Wall Street's forecast of $0.52. Small-cap stocks outperformed, with the Russell 2000 Index climbing 2.3%. This, along with strength in AMZN, helped the Nasdaq Composite (+1.1%) outpace the Dow (+0.4%) and S&P 500, which only contain large-cap stocks.DJ30 +48.03 NASDAQ +25.85 NQ100 +0.8% R2K +2.3% SP400 +0.9% SP500 +9.00 NASDAQ Adv/Vol/Dec 1993/2.30 bln/857 NYSE Adv/Vol/Dec 1955/1.26 bln/1158 ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway, GO TO: www.investsourceinc.com. Coming in late Summer of this year: Go Baby GO!!! The first book of its kind on the OTCBB and Pink Sheet Markets www.gobabygobook.com . To hear "The Fastest 60 Seconds in the Small-Cap Market," please go to www.ceo-corner.com InvestSource, Inc. is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. InvestSource, Inc. affiliates, officers, directors and employees may also have bought, or may buy the shares discussed in this opinion and may profit in the event of a rise in value. InvestSource, Inc. will not advise as to when it decides to sell and does not, and will not, offer any opinion as to when others should buy or sell; each investor must make that decision based on his or her judgment of the market InvestSource has received 5 million shares of Greenstone Holdings for services rendered. Please consult your broker before purchasing or selling any securities mentioned herein. To view full disclaimers, please go to http://investsourceinc.com/php/disclaimer.php (disclaimers). This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The information contained in an InvestSource profile is provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. CONTACT: InvestSource, Inc e-mail: [email protected] WWW: http://www.investsourceinc.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2008 M2 Communications Ltd. |